XNCR

Based on Xencor, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does Xencor do?

Xencor is a clinical-stage biopharmaceutical company that engineers monoclonal antibodies and cytokine therapeutics. It develops treatments for cancer and autoimmune diseases through its proprietary XmAb technology platform, which it also licenses to larger pharmaceutical partners in exchange for milestones and royalties.

Does XNCR pay dividends?

No, Xencor does not currently pay a dividend. As a clinical-stage company, it reinvests available capital into research, clinical trials, and platform development. Income-focused investors should be aware that distributions are not part of Xencor's current capital allocation strategy.

When does XNCR report earnings?

Xencor reports on a standard quarterly schedule. Because it is a clinical-stage company, results often hinge on collaboration revenue timing and trial costs rather than product sales. Check Xencor's investor relations page for the most current reporting calendar.

Is XNCR a good stock to buy?

UQS Score rates XNCR as Poor overall. The Risk pillar is a relative strength, but Quality and Moat both register as Weak, and Valuation reads as Elevated. Investors should weigh the pipeline optionality against the current pricing and limited near-term commercial revenue. The full pillar breakdown is available to Pro members.

Is XNCR overvalued?

The UQS Valuation pillar for XNCR is rated Elevated, suggesting the stock may be pricing in optimistic pipeline outcomes relative to its current fundamental profile. Clinical-stage biotechs often carry premium valuations tied to future potential, which can compress if trial results disappoint.

How does XNCR compare to its competitors?

Compared to peers like Janux Therapeutics and Omeros, Xencor differentiates through its broad XmAb platform and established licensing partnerships. However, all three operate in high-risk clinical development environments. The UQS Score comparison for each peer is available on their respective pages.

What is XNCR's market cap bracket?

Xencor is classified as a small-cap company. This places it in a segment of the market that can offer higher growth potential but typically carries greater volatility and liquidity risk compared to large- or mega-cap peers in the healthcare sector.

Who founded Xencor?

Xencor was founded in 2013 and is headquartered in Pasadena, California. For detailed founding history and leadership background, Xencor's official about page and public filings provide comprehensive information.

Is XNCR a long-term quality investment?

As a long-term quality indicator, XNCR's UQS Score of Poor reflects current weaknesses in Quality and Moat that are common for pre-commercial biotechs. Long-term quality depends heavily on whether pipeline candidates achieve regulatory approval and generate durable revenue. The Risk pillar's strength does provide some financial stability in the interim.

What is the main competitive advantage of Xencor?

Xencor's primary differentiator is its XmAb engineering platform, which allows it to design antibodies with enhanced properties and license that technology to major pharmaceutical companies. This creates a royalty and milestone revenue stream that partially offsets the costs of its internal pipeline development.

What sector does XNCR belong to?

Xencor operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. Its focus on engineered antibody therapeutics places it in a specialized niche that intersects oncology and immunology drug development.

Is XNCR a growth stock or value stock?

Based on its UQS profile, XNCR leans toward a growth-oriented positioning — its Growth pillar is Neutral and its Valuation pillar is Elevated, meaning the market is assigning a premium relative to current fundamentals. It does not exhibit the characteristics typically associated with value stocks.

Xencor, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.

Xencor, Inc. faces growth headwinds with declining or stagnant revenue trends.

Xencor, Inc. carries minimal financial risk with conservative leverage and strong solvency.

Xencor, Inc. appears expensively valued relative to its fundamentals and growth prospects.

Xencor, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for XNCR.

The UQS (Unified Quality Score) for Xencor, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Xencor, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Xencor, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.